Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sunday newspaper round-up: Bank of England, Sturgeon, Melrose

(Sharecast News) - Experts believe that the Bank of England will have to jack up its base rate from 4.5% at present to 5.5% by the end of 2023 in order to tame stubbornly high inflation. It was that prospect that had already resulted in lenders and building societies to raise the cost of fixed-rate mortgages or to pull deals altogether, as HSBC did during the preceding week. Higher rates also have implications for the cost of servicing the country's debts, in turn eliminating the Chancellor's already limited headroom to push through tax cuts before the elections. - The Financial Mail on Sunday Police looking into accusations of financial misconduct by the Scottish National Party have arrested one of its former leaders, Nicola Sturgeon. Sturgeon was one of three individuals arrested as part of Operation Branchform, which is investigating whether £600,000-worth of donations to the independence campaign had been misspent by the party. - Guardian

Melrose boss Simon Peckham made a staunch defence of the takeover outfit in an interview. The executive said predator firms like his were necessary in markets in order to restructure poorly-run corporations that would otherwise just carry on underperforming. But he derided criticism of the firm as slash and burn merchants. Quite the opposite, Melrose had pumped over £1bn into GKN Aerospace. There were about 12 months of hard work left in order to spruce it up, he added. Indeed, Melrose "lover buying businesses and seeing them get better". - The Financial Mail on Sunday

Jeb Smith - also known as "the most feared man in corporate America" - has UK biotech outfit Abcam in its sights. Starboard Value, the hedge fund run by Smith, has taken a roughly 2% stake in the antibody company. Last year, Abcam shelved plans for a London float, instead pursuing a listing on the US Nasdaq Exchange. In parallel, Abcam's founders, Jonathan Milner, is pushing to be reinstalled as executive chairman. On Monday he will send a note to investors arguing that only under his leadership can the company undo its "sustained financial underperformance and value destruction". A spokesman for the company however said that Milner's claim were without merit. - Sunday Times

Share this article

Related Sharecast Articles

Thursday newspaper round-up: Thames Water, mortgage costs, UK car production
(Sharecast News) - Thames Water has breached its licence to supply water to nearly 16 million people after some of its debt was downgraded to junk status. The regulator Ofwat could now fine Thames, the country's largest water monopoly, up to 10% of its annual turnover, equating to hundreds of millions of pounds. However, since the company is already teetering close to temporary renationalisation, Ofwat is likely to hold off on any immediate large fines. - Guardian
Wednesday newspaper round-up: Reckitt, Tesla, Virgin Atlantic...
(Sharecast News) - Reckitt is under pressure from top shareholders to revisit a sale of its nutrition business, following litigation and a series of other setbacks at the division that have sent the company's share price to decade lows. The FTSE 100 consumer giant acquired the Mead Johnson infant formula business in 2017 for $17bn - its largest-ever acquisition - and it has been plagued by mishaps ever since. Meanwhile, the wider group, which makes Lysol detergent and Durex condoms, has underwhelmed investors as it struggles to build back sales volumes following a period of high inflation and suppressed consumer demand. - Financial Times
Tuesday newspaper round-up: Kamala Harris, Crowdstrike, Vivendi...
(Sharecast News) - Kamala Harris has secured enough delegates from her party to clinch the Democratic presidential nomination, as she pledged to offer Americans a "brighter future" compared to the "chaos, fear and hate" proposed by Donald Trump. The US vice-president was speaking in Wilmington, Delaware, on Monday, the first full day since President Joe Biden dropped his re-election bid and endorsed her for the Democratic presidential nomination, shaking up the 2024 race for the White House. - Financial Times
Monday newspaper round-up: Biden, gambling levy, UK economy...
(Sharecast News) - Kamala Harris, the vice-president, has emerged as the frontrunner to replace President Biden as the Democratic nominee for the election against Donald Trump in November. Biden, 81, announced yesterday afternoon that he would drop out of the race. In the hours that followed, Harris, 59, was endorsed by leading Democrats, prospective rivals and the chairs of all 50 state parties. - The Times

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.